最新ニュース CVS Health (NYSE:CVS) 株価情報

CVS Health

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.

CVS Health Corp

Morgan Stanley ETF Trust Calvert Ultra-Short Investment Grade ETF

CARDIOVASCULAR SCI INC by Cardiovascular Sciences, Inc.

Morgan Stanley ETF Trust Calvert US Select Equity ETF

CVS Group PLC

CIVITAS SOCIAL HSG PLC by CIVITAS SOCIAL HSG PLC

CV Sciences Inc

COVISTA COMMUNS INC by Covista Communications, Inc,

Covista Communications Inc

CONVERGENCE SYS INC CL A by Convergence Systems Inc.

Convergence Systems Inc

As the formal review process for rescheduling cannabis unfolds, industry players are closely watching its potential to transform the sector. With the DEA hearing delayed until early 2025 and a possible Trump presidency adding uncertainty, cannabis businesses are preparing for what rescheduling to Schedule III could mean.&nbsp;
From FDA oversight to interstate commerce and pharmaceutical-grade standards, these changes could fundamentally reshape the landscape—and investors and businesses need to be ready.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h2 class="wp-block-heading">Rescheduling: A Door To Big-Box Pharmacies?</h2>
Denise Pollicella, a cannabis attorney and head of Omnus Law&#8216;s cannabis practice, points out that rescheduling cannabis isn't just about new retail partnerships but about overhauling how cannabis businesses operate.&nbsp;
"It's about transforming how cannabis businesses operate—adapting to FDA oversight, meeting pharmaceutical-grade standards, and navigating stricter compliance requirements," she told Benzinga Cannabis in an exclusive interview.
Rescheduling to Schedule III could allow major pharmaceutical retailers like CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and Walgreens (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) to carry cannabis. But is the pathway straightforward? 
Pollicella anticipates a system similar to the <a href="https://www.benzinga.com/government/regulations/24/11/42068539/billion-dollar-strike-farm-bill-amendment-could-change-the-hemp-industry">2018 hemp legalization framework</a>, where states submit regulatory schemes to meet federal guidelines. "Most states prefer to regulate these things themselves, particularly from a financial and tax point of view," she said, noting states' interest in retaining control of fees and fines.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="500" height="500" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28053734/Denise-Pollicella-Square-Website-Image.png" alt="" class="wp-image-668972" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28053734/Denise-Pollicella-Square-Website-Image.png 500w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28053734/Denise-Pollicella-Square-Website-Image-300x300.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28053734/Denise-Pollicella-Square-Website-Image-150x150.png 150w" sizes="(max-width: 500px) 100vw, 500px" /><figcaption class="wp-element-caption">Denise Pollicella </figcaption></figure>
<h3 class="wp-block-heading">FDA Oversight: Stricter Standards Ahead</h3>
If cannabis becomes a pharmaceutical-grade product, compliance with<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33482140/rescheduling-cannabis-what-are-the-implications-for-msos-tax-rule-280e-fda-and-phar"> FDA standards will significantly change how businesses operate</a>. Pollicella explained that the cannabis industry has historically focused on ensuring safety and avoiding contaminants, with minimal emphasis on seed traceability. "Most of the testing and analysis has revolved around making sure that it's safe and doesn't have contaminants, and then around THC and CBD levels," she noted.
Pollicella added that transitioning to pharmaceutical-grade products would require stricter production standards and significantly more testing, which could drive up costs in an already expensive industry. Pollicella noted the likely challenges: "When it goes to a more pharmaceutical-grade product, not only will the production standards have to become more strict, but you'll also have significantly more testing."
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/07/39720968/is-big-pharma-poised-to-take-over-cannabis-3-companies-already-manage-8-in-10-drug-prescriptions"> Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US</a>
<h3 class="wp-block-heading">Interstate Commerce</h3>
<a href="https://www.benzinga.com/markets/cannabis/24/10/41502695/exclusive-tilray-ceo-irwin-simon-on-why-us-cannabis-rescheduling-wont-change-a-billion-dollar-pl">Rescheduling cannabis from Schedule I to Schedule III </a>could pave the way for interstate trade, a shift that would fundamentally reshape supply chains and market dynamics. By lowering cannabis&#8217;s federal regulatory classification, rescheduling would enable cannabis to be treated more like other pharmaceutical products, potentially allowing producers in one state to sell to buyers in another. However, this transition would introduce new regulatory complexities.
Pollicella thinks that cannabis crossing state lines will require permissions, excise taxes, and strict identification as medical marijuana, and noted that states with mature medical markets, such as <a href="https://www.benzinga.com/topic/michigan-cannabis">Michigan</a>, <a href="https://www.benzinga.com/topic/pennsylvania-cannabis">Pennsylvania</a>, and <a href="https://www.benzinga.com/topic/florida-cannabis">Florida</a>, could dominate the wholesale market. 
MSOs operating in these states include TerrAscend (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRSSF#OTC">TRSSF</a>), Cresco Labs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) in Michigan; Green Thumb Industries Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>), Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), and Verano Holdings Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>) in Pennsylvania; and Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) and Ayr Wellness Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>) in Florida.
These companies have heavily invested in CapEx for pharmaceutical-grade cannabis to meet stringent standards aligned with FDA requirements, positioning them to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39609582/europe-is-turning-cash-flow-positive-well-see-what-happens-in-the-u-s-largest-canna">supply pharmacies and other large-scale buyers</a>. "Michigan has tried to position itself as being nearly equal to FDA standards," Pollicella explained, highlighting the state's competitive advantage.&nbsp;
<h3 class="wp-block-heading">M&amp;A Activity: A Rescheduled Catalyst? </h3>
The prospect of federal rescheduling is already sparking discussions about mergers and acquisitions. Pollicella foresees significant consolidation as businesses struggle to meet pharmaceutical-grade compliance. "Companies that have grown thoughtfully and in a measured way are going to knock it out of the park," she said, emphasizing the Darwinian nature of the cannabis business.
Midwest markets, like Michigan and Illinois, are expected to play pivotal roles in<a href="https://www.benzinga.com/cannabis/deals"> M&amp;A activity</a>. Pollicella highlighted Michigan's readiness, citing its strict testing standards and proactive lobbying efforts. &#8220;Michigan has tried to position itself as being nearly equal to FDA standards,&#8221; she explained, adding that the state could become a major producer for the Midwest.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/05/38881456/bidens-greenlight-what-to-know-about-fed-regulated-marijuana-markets-legal-circuits-and-complian"> Biden&#8217;s Greenlight: What To Know About Fed-Regulated Marijuana, Markets, Legal Circuits And Compliance</a>
<h2 class="wp-block-heading">Will A Trump Presidency Delay Progress?</h2>
Pollicella warns that<a href="https://www.benzinga.com/news/legal/24/11/42143770/trumps-pick-for-attorney-general-is-no-matt-gaetz-when-it-comes-to-cannabis-reform"> rescheduling is far from guaranteed.</a> "Anybody counting on the rescheduling of marijuana down to Schedule III in the new administration is making an assumption that's not necessarily based on anything we've seen yet," she cautioned.
While some industry advocates hope the promise of tax revenue and economic growth will sway federal policymakers, Pollicella remains skeptical. "It's not a priority for this administration," she said, adding that substantial lobbying will likely be needed to make progress.
<h3 class="wp-block-heading">2025</h3>
Despite the challenges, Pollicella is optimistic about the industry's potential under a rescheduled framework. She believes businesses with scalable production capabilities and strategic foresight will thrive. However, she also underscores the need for readiness.&nbsp;
Despite the significant political and economic discussions surrounding cannabis rescheduling, the process itself is more straightforward than many assume. Pollicella explains that the Controlled Substances Act of 1970 placed cannabis on Schedule I through political and legislative decisions, rather than medical consensus. "None of the criteria for Schedule I—no known medical use, no known safe use, and a high probability of addictiveness—really apply to marijuana," she said. As with its initial classification, rescheduling will require bipartisan consensus and can follow one of two paths.
Congress could pass legislation to amend the Controlled Substances Act, or the Attorney General could direct the FDA and <a href="https://www.benzinga.com/24/11/42144540/dea-slammed-over-unlawful-talks-with-cannabis-opponents-the-plot-thickens">DEA to conduct a review</a> and implement rescheduling through administrative rule-making.&nbsp;
Read Also: <a href="https://www.benzinga.com/24/11/42220254/dea-sets-stage-for-marijuana-rescheduling-with-december-2-hearing">DEA Sets Stage For Marijuana Rescheduling With December 2 Hearing</a>
<h3 class="wp-block-heading">Political Will </h3>
"Once there's political will, it can happen like this," Pollicella said, snapping her fingers metaphorically to illustrate how quickly the process could move once initiated.
This swift <a href="https://www.benzinga.com/markets/cannabis/24/08/40632193/marijuana-rescheduling-is-not-solution-to-industrys-banking-issues-congressional-researchers-say">rescheduling would require states to align their regulatory schemes with federal guidelines</a>. Pollicella anticipates that it might follow a model similar to the 2018 hemp rollout:&nbsp;
"The <a href="https://www.benzinga.com/government/regulations/24/11/41936736/fda-commissioner-califf-candid-on-trumps-impact-we-just-dont-know-whats-going-to-happen">FDA</a> could give states with existing regulatory structures a timeline, say six to nine months, to refine their programs<a href="https://www.benzinga.com/general/biotech/24/09/40820581/want-organic-cannabis-operators-are-turning-to-this-tech-to-save-millions-and-get-certified"> to meet federal standards</a>. States that comply could maintain control, while those that don't might see federal intervention."
However, the question remains whether the upcoming administration will prioritize this process. "The real challenge isn't the steps—it's the political will to move forward," she noted.
Read Next: <a href="https://www.benzinga.com/news/retail-sales/24/11/42193387/federal-policy-could-add-3-billion-to-cannabis-industry-on-track-to-reach-55-billion-by-2030">Federal Policy Could Add $3 Billion To Cannabis Industry: On Track To Reach $55 Billion By 2030</a>

Cannabis

Government

Market Summary

News

Regulations

Health Care

Retail Sales

Legal

Management

Exclusives

Markets

Trading Ideas

Interview

AYRWF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

TRSSF

VRNOF

Pharma-Grade Cannabis Could Hit Walgreens & CVS—But Can The Industry Survive The FDA?

Fernando Aguirre, Director at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), disclosed an insider purchase on November 25, based on a new SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224027994//Archives/edgar/data/64803/000112760224027994/0001127602-24-027994-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Aguirre purchased 2,364 shares of CVS Health, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $134,984.
The latest market snapshot at Tuesday morning reveals CVS Health shares down by 2.09%, trading at $58.83.
<h3>Discovering CVS Health: A Closer Look</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>CVS Health: Delving into Financials</h3>
Revenue Growth: CVS Health's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.31%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a low gross margin of 13.16%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): CVS Health's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.07.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 1.1, CVS Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 15.25 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.21 is lower than the industry average, implying a discounted valuation for CVS Health's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): CVS Health's EV/EBITDA ratio, lower than industry averages at 10.47, indicates attractively priced shares.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

134K Reasons To Be Bullish On CVS Health Stock

A significant insider buy by Jeffrey R Balser, Director at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), was executed on November 25, and reported in the recent SEC filing.
What Happened: In a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224027995//Archives/edgar/data/64803/000112760224027995/0001127602-24-027995-index.htm">U.S. Securities and Exchange Commission</a>, it was disclosed that Balser bought 2,375 shares of CVS Health, amounting to a total of $135,612.
CVS Health's shares are actively trading at $58.83, experiencing a down of 2.09% during Tuesday's morning session.
<h3>Unveiling the Story Behind CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>Understanding the Numbers: CVS Health's Finances</h3>
Revenue Growth: Over the 3 months period, CVS Health showcased positive performance, achieving a revenue growth rate of 6.31% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 13.16%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): CVS Health's EPS reflects a decline, falling below the industry average with a current EPS of 0.07.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 1.1, CVS Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 15.25 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.21 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 10.47, CVS Health presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Move: Jeffrey R Balser Invests $135K In CVS Health Stock

A significant insider buy by C. David Brown II, Director at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), was executed on November 25, and reported in the recent SEC filing.
What Happened: In a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224027996//Archives/edgar/data/64803/000112760224027996/0001127602-24-027996-index.htm">U.S. Securities and Exchange Commission</a>, it was disclosed that II bought 2,331 shares of CVS Health, amounting to a total of $133,100.
The latest update on Tuesday morning shows CVS Health shares down by 2.09%, trading at $58.82.
<h3>Get to Know CVS Health Better</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>CVS Health's Financial Performance</h3>
Revenue Growth: CVS Health's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.31%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 13.16%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, CVS Health exhibits below-average bottom-line performance with a current EPS of 0.07.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.1.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: CVS Health's P/E ratio of 15.25 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.21 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 10.47, CVS Health presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

C. David Brown II Of CVS Health Shows Optimism, Buys $133K In Stock

Nancy-Ann M. DeParle, Board Member at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), disclosed an insider purchase on November 25, based on a new SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224027998//Archives/edgar/data/64803/000112760224027998/0001127602-24-027998-index.htm">U.S. Securities and Exchange Commission</a> on Monday unveiled that DeParle made a notable purchase of 2,331 shares of CVS Health, valuing at $133,100.
At Tuesday morning, CVS Health shares are down by 2.09%, trading at $58.82.
<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>A Deep Dive into CVS Health's Financials</h3>
Revenue Growth: Over the 3 months period, CVS Health showcased positive performance, achieving a revenue growth rate of 6.31% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 13.16%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): CVS Health's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.07.
</li>
</ul>
Debt Management: CVS Health's debt-to-equity ratio is below the industry average. With a ratio of 1.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 15.25 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.21 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 10.47, CVS Health presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVS Health Insider Trades SendAa Signal

A notable insider purchase on November 25, was reported by J. Scott Kirby, Director at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), based on the most recent SEC filing.
What Happened: Kirby demonstrated confidence in CVS Health by purchasing 2,933 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224028000//Archives/edgar/data/64803/000112760224028000/0001127602-24-028000-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value of the transaction is $167,474.
Tracking the Tuesday's morning session, CVS Health shares are trading at $58.82, showing a down of 2.09%.
<h3>Unveiling the Story Behind CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>CVS Health: Financial Performance Dissected</h3>
Positive Revenue Trend: Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.31% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 13.16%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): CVS Health's EPS is below the industry average. The company faced challenges with a current EPS of 0.07. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 1.1, CVS Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.25 is lower than the industry average, implying a discounted valuation for CVS Health's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.21, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): CVS Health's EV/EBITDA ratio at 10.47 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Massive Insider Trade At CVS Health

It was revealed in a recent SEC filing that Michael F Mahoney, Director at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) made a noteworthy insider purchase on November 25,.
What Happened: Mahoney's recent move, as outlined in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224028001//Archives/edgar/data/64803/000112760224028001/0001127602-24-028001-index.htm">U.S. Securities and Exchange Commission</a> on Monday, involves purchasing 2,200 shares of CVS Health. The total transaction value is $125,620.
Tracking the Tuesday's morning session, CVS Health shares are trading at $58.82, showing a down of 2.09%.
<h3>Get to Know CVS Health Better</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>CVS Health: Delving into Financials</h3>
Positive Revenue Trend: Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.31% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a low gross margin of 13.16%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): CVS Health's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.07.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.1.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.25 is lower than the industry average, implying a discounted valuation for CVS Health's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.21, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 10.47 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bullish Move: Michael F Mahoney Shows Confidence, Acquires $125K In CVS Health Stock

A notable insider purchase on November 25, was reported by Jean-Pierre Millon, Director at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), based on the most recent SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224028002//Archives/edgar/data/64803/000112760224028002/0001127602-24-028002-index.htm">U.S. Securities and Exchange Commission</a> on Monday unveiled that Millon made a notable purchase of 2,200 shares of CVS Health, valuing at $125,620.
At Tuesday morning, CVS Health shares are down by 2.09%, trading at $58.82.
<h3>Delving into CVS Health's Background</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>Key Indicators: CVS Health's Financial Health</h3>
Revenue Growth: CVS Health's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.31%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 13.16%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): CVS Health's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.07.
</li>
</ul>
Debt Management: CVS Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.1.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 15.25, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.21 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 10.47, CVS Health presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Major Purchase Alert: Jean-Pierre Millon Invests $125K In CVS Health Stock

Leslie V Norwalk, Director at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), disclosed an insider purchase on November 25, based on a new SEC filing.
What Happened: Norwalk's recent move, as outlined in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224028008//Archives/edgar/data/64803/000112760224028008/0001127602-24-028008-index.htm">U.S. Securities and Exchange Commission</a> on Monday, involves purchasing 2,200 shares of CVS Health. The total transaction value is $125,620.
Monitoring the market, CVS Health's shares down by 2.08% at $58.83 during Tuesday's morning.
<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>CVS Health's Financial Performance</h3>
Revenue Growth: CVS Health's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 13.16%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): CVS Health's EPS reflects a decline, falling below the industry average with a current EPS of 0.07.
</li>
</ul>
Debt Management: CVS Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.1.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 15.25 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.21, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 10.47 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Smart Money Move: Leslie V Norwalk Grabs $125K Worth Of CVS Health Stock

On November 25, Guy P Sansone, Board Member at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224028009//Archives/edgar/data/64803/000112760224028009/0001127602-24-028009-index.htm">U.S. Securities and Exchange Commission</a> on Monday unveiled that Sansone made a notable purchase of 2,200 shares of CVS Health, valuing at $125,620.
During Tuesday's morning session, CVS Health shares down by 2.08%, currently priced at $58.83.
<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>Unraveling the Financial Story of CVS Health</h3>
Revenue Growth: CVS Health's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 13.16%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): CVS Health's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.07.
</li>
</ul>
Debt Management: CVS Health's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: CVS Health's P/E ratio of 15.25 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.21 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 10.47, CVS Health's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVS Health Board Member Makes $125K Stock Purchase

Disclosed in the latest SEC filing, a significant insider purchase on November 25, involves Douglas H Shulman, Board Member at CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000064803/000112760224028010//Archives/edgar/data/64803/000112760224028010/0001127602-24-028010-index.htm">U.S. Securities and Exchange Commission</a> on Monday unveiled that Shulman made a notable purchase of 2,200 shares of CVS Health, valuing at $125,620.
During Tuesday's morning session, CVS Health shares down by 2.06%, currently priced at $58.84.
<h3>Discovering CVS Health: A Closer Look</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>Understanding the Numbers: CVS Health's Finances</h3>
Revenue Growth: CVS Health's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 13.16%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, CVS Health exhibits below-average bottom-line performance with a current EPS of 0.07.
</li>
</ul>
Debt Management: CVS Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.1.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: CVS Health's P/E ratio of 15.25 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.21, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): CVS Health's EV/EBITDA ratio, lower than industry averages at 10.47, indicates attractively priced shares.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000064803">Check Out The Full List Of CVS Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member Of CVS Health Purchased $125K In Stock

WIIM

CVS Health shares are trading higher after Cowen maintained its Buy rating and raised its price target from $73 to $80. Piper Sandler also maintained its Overweight rating, but lowered its price target from $72 to $64.

TD Cowen analyst Charles Ryhee maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $73 to $80.

Price Target

Analyst Ratings

TD Cowen Maintains Buy on CVS Health, Raises Price Target to $80

Piper Sandler analyst Jessica Tassan maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and lowers the price target from $72 to $64.

Piper Sandler Maintains Overweight on CVS Health, Lowers Price Target to $64

Wedbush Securities has issued an endorsement of the artificial intelligence software sector, with Managing Director Dan Ives predicting that 2025 will be a pivotal year for AI implementation across the industry. This comes as Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) continues its remarkable ascent, <a href="https://www.benzinga.com/24/11/42143996/daddys-home-palantir-creates-two-new-billionaires-after-trumps-win-both-own-less-than-2-stock-and-are-thiels-favorites">having surged 288% year-to-date</a>.
What Happened: In a notable sector-wide upgrade, Ives raised Palantir&#8217;s price target to $75 while upgrading both Elastic NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) and Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) to Buy ratings. He also increased Salesforce Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) price target to $375, signaling broader confidence in the software sector&#8217;s AI potential.
&#8220;The AI Revolution is accelerating and now it&#8217;s the software sector that will benefit from the use case phase of AI set to be primetime in 2025,&#8221; Ives <a href="https://x.com/DivesTech/status/1860816966367281267">wrote</a>, adding, &#8220;Software AI age here.&#8221;
The bullish outlook aligns with <a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap">Palantir&#8217;s recent performance</a>, which has seen its market capitalization soar to approximately $140 billion, surpassing defense contractor Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>). The company&#8217;s growth has been particularly notable following recent political developments, with its stock reaching $61 per share.
See Also: <a href="https://www.benzinga.com/general/social-media/24/11/42155884/economist-slams-doges-simplistic-approach-to-government-spending-questions-super-bowl-ad-criticism">Economist Slams DOGE: Tells Elon Musk-Led Initiative To &#8216;Do Your Legal Job Well&#8217; Amid Super Bowl Ad Spending Clash</a>
Why It Matters: Palantir&#8217;s momentum is supported by concrete achievements, including a $480 million Pentagon contract for Project Maven and its first profitable year in 2023, reporting $144 million in <a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap">third-quarter net income</a>. 
The company has successfully expanded its <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42039361/palantir-soars-to-150b-market-cap-as-analysts-flag-risks-in-valuation-insider-sales">commercial sector revenue</a> to 35% of total earnings, securing major contracts with CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and BP plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>).
However, some investors express caution regarding valuations. Major hedge funds, including Renaissance Technologies and ARK Investment Management, reduced their Palantir <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42039361/palantir-soars-to-150b-market-cap-as-analysts-flag-risks-in-valuation-insider-sales">holdings in the third quarter</a>, though maintaining significant positions. 
The company&#8217;s P/E ratio of 328.85 and heavy retail investor base of approximately 50% have prompted discussions about <a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap">potential market volatility</a>.
Price Action: Palantir&#8217;s stock closed at $64.35 on Friday, gaining 4.87% during the regular trading session. In after-hours trading, the stock dipped slightly by 0.20%. Year-to-date, Palantir has seen a remarkable surge of 288.12%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42155405/mcdonalds-spends-100-million-after-e-coli-outbreak-as-trust-and-love-must-be-rebuilt-says-chief-impact-officer">McDonald&#8217;s Spends $100 Million After E. Coli Outbreak As &#8216;Trust And Love&#8217; Must Be Rebuilt, Says Chief Impact Officer</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

ESTC

PLTR

SNOW

Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge: Analyst Calls 2025 A 'Primetime' Year For AI

CVS Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has risen 5.45% since its last report. The company recently reported that it has 21.85 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732214715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CVS Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 8.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CVS) - Analyzing CVS Health's Short Interest

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul>
<li>Dividend Yield: 6.74%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and boosted the price target from $28 to $29 on May 2. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Nov. 20, Pfizer announced new Chief Scientific Officer and President, Research &amp; Development.</li>
<li>Benzinga Pro's real-time newsfeed alerted to la<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">test PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218.png" alt="" class="wp-image-658993" style="width:747px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218-768x703.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 5.18%</li>
<li>Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 78%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and cut the price target from $35 to $28 on June 20. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On Nov. 13, Patterson Dental extended strategic relationship with PDS Health.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest PDCO news </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="883" height="655" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219.png" alt="" class="wp-image-658996" style="width:685px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219.png 883w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219-300x223.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219-768x570.png 768w" sizes="(max-width: 883px) 100vw, 883px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.68%</li>
<li>Truist Securities analyst David Macdonald reiterated a Buy rating and cut the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 67%.</li>
<li>UBS analyst Kevin Celiendo maintained a Neutral rating and raised the price target from $60 to $62 on Nov. 7. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Nov. 18, CVS Health announced the addition of four new directors to its board.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">in CVS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="847" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220.png" alt="" class="wp-image-658999" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220.png 847w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-300x300.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-150x150.png 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-768x771.png 768w" sizes="(max-width: 847px) 100vw, 847px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42103475/nvidia-deere-and-3-stocks-to-watch-heading-into-thursday">Nvidia, Deere And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Pre-Market Outlook

PDCO

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields

As President-elect Donald Trump prepares to return to the White House, renowned economist Mohamed El-Erian is cautioning against media oversimplification of the incoming administration&#8217;s proposed tariff strategies.
What Happened: In a recent statement on X, El-Erian highlighted the intricate nature of Trump&#8217;s tariff discussions, noting that the proposed economic policies encompass at least three complex economic stages influenced by multiple factors, including trade flows, corporate pricing strategies, and geopolitical considerations.
El-Erian&#8217;s core message remains clear: Trump&#8217;s tariff debate requires sophisticated, nuanced analysis that transcends simplistic narratives. &#8220;The issue is quite complex,&#8221; he emphasized, underscoring the need for comprehensive economic understanding beyond headline rhetoric.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It should come as no surprise that the media tends to oversimplify the U.S. tariff debate, with both sides of the argument contributing to this. The issue is quite complex, involving at least three economic stages, each with various possibilities given the influences in play. The…
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1859287383075848351?ref_src=twsrc%5Etfw">November 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trump&#8217;s proposed economic blueprint, which includes a universal tariff of up to 20% on imports and potentially up to 60% on Chinese goods, has sparked intense economic debate. Tech investor Peter Thiel suggests these tariffs could significantly impact Chinese companies while causing minimal <a href="https://www.benzinga.com/markets/24/11/42028954/peter-thiel-says-trumps-60-china-tariff-would-be-very-very-bad-for-beijing-heres-whats-at-stake">disruption to U.S. consumers</a>.
See Also: <a href="https://www.benzinga.com/24/11/42102366/bitcoin-taps-95k-ethereum-dogecoin-flat-as-trumps-crypto-policy-takes-shape-top-analyst-describes-btcs-path-to-135k">Bitcoin Hits $95K For The First Time Ever, Ethereum, Dogecoin Flat As Trump&#8217;s Crypto Policy Takes Shape: Top Analyst Describes BTC&#8217;s Path To $135K</a>
Why It Matters: Goldman Sachs economist David Mericle warns that Trump&#8217;s proposed universal tariff could push <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">inflation back to 3%</a>, potentially complicating Federal Reserve monetary strategies. 
The National Retail Federation estimates Trump&#8217;s tariff proposals could reduce annual consumer <a href="https://www.benzinga.com/news/24/11/41737933/trump-tariff-proposed-may-cost-americans-78b-in-spending-study">spending by $78 billion</a>.
Prominent business leaders have voiced concerns. Citadel LLC CEO Ken Griffin described Trump&#8217;s proposed tariffs as a &#8220;long, slippery slope&#8221; that <a href="https://www.benzinga.com/news/global/24/11/42056528/gop-megadonor-ken-griffin-warns-of-slippery-slope-in-trumps-tariff-policies-sees-us-returning-to-the-business-of-business">could hamper U.S. global competitiveness</a>. 
Retailers like AutoZone and Columbia Sportswear have signaled potential price increases that would be <a href="https://www.benzinga.com/news/24/11/41871407/trumps-tariffs-deportations-and-tax-cuts-may-push-prices-higher-experts-say-its-pretty-clear?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=site&amp;nid=42027079">passed directly to consumers</a>.
"Tariffs would create a headwind to the performance of stocks with high international revenue exposure due to the risk of retaliatory tariffs and heightened geopolitical tensions," Goldman Sachs analyst David Kostin stated.
Goldman Sachs noted that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39467825/us-election-and-tariff-prospects-set-to-threaten-internationally-exposed-stocks-gol">U.S. stocks with domestic sales focus outperformed</a> those with international exposure by 1 percentage point the day after Trump's election and by 4 pp in the following month but underperformed by 9 pp in the next 12 months.
Key stocks in its Domestic Sales Basket include CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), Lowe's Cos. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>), and Union Pacific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>).
The International Sales Basket includes Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), QUALCOMM Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), McDonald's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), and Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>).
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">Dollar Upside On The Cards Amid Geopolitical Tensions, Cautious Fed And Solid US Economic Data, Says Expert</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Economics

AMAT

AVGO

INTC

INTU

NFLX

QCOM

TMUS

Mohamed El-Erian Warns Against Simplistic Narratives As Trump Plans Aggressive Tariff Strategy: 'The Issue Is Quite Complex'

The Federal Trade Commission (FTC) is facing legal challenges from three competing pharmacy-benefit managers (PBMs) over its attempt to restrict their ability to negotiate drug prices for <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit" rel="noreferrer noopener">health plan sponsors</a>.
In September, the FTC filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.
The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.
The companies also <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/ExpressScriptsIncetalvFederalTradeCommissionetalDocketNo424cv0154?doc_id=X11H3MUIQJ4995RQ9NSUPGSE2AP" rel="noreferrer noopener">contend</a> that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.
The lawsuit stems from the FTC&#8217;s attempt to regulate the drug rebate system, allowing PBMs to secure manufacturers&#8217; discounts.
However, the FTC&#8217;s complaint accuses the PBMs of using their power to create an unfair market, alleging that the system allows drug manufacturers to inflate prices.
In challenging the FTC&#8217;s action, the PBMs argue that this is not just a market dispute but a constitutional issue.
They assert that the FTC&#8217;s administrative proceeding, taking place in an in-house forum where the agency decides the facts, the law, and the outcome, is unconstitutional.
Furthermore, the PBMs argue that the FTC&#8217;s decision to handle the case through this in-house process, with a partisan panel of Democratic commissioners, deprives them of a fair trial.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap" target="_blank" rel="noreferrer noopener">Palantir Tech&#8217;s $140 Billion Market Cap Gain Is Driven By Trump&#8217;s Victory And Higher Defense Spending Hope &#8211; Is The Stock Overvalued?</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Large Cap

General

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System

Truist Securities analyst David Macdonald reiterates CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and lowers the price target from $76 to $67.

Reiteration

Truist Securities Reiterates Buy on CVS Health, Lowers Price Target to $67

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

Here are the top industries and stocks that were impacted by the comments, actions and policies of President-elect Trump this week compiled by The ...

Trump Weekly: Trump looks to drop EV tax credit, fuel-efficiency requirements

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price target was raised to...

CVS Health's Strategic Turnaround: Poised for Growth in Medicare Advantage and Market Share Gains by 2025

Piper Sandler analyst Jessica Tassan maintained a Buy rating on CVS Health (CVS – Research Report) today and set a price target of $64.00. The comp...

Piper Sandler Sticks to Their Buy Rating for CVS Health (CVS)

Piper Sandler lowered the firm's price target on CVS Health (CVS) to $64 from $72 and keeps an Overweight rating on the shares. The firm believes C...

CVS Health price target lowered to $64 from $72 at Piper Sandler

TD Cowen analyst Charles Rhyee raised the firm's price target on CVS Health (CVS) to $80 from $73 and keeps a Buy rating on the shares. The firm sa...

CVS Health price target raised to $80 from $73 at TD Cowen

Biden administration proposes expanded obesity drug coverage under Medicare, Medicaid

RBC Capital sees little reason for concern over CMS' proposed GLP-1 coverage rule and its potential impact on MCOs. Should the rule go into effect ...

Comments

CVS Health

ニュース

最新ニュース CVS Health (NYSE:CVS) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル